This company is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model.
1 Like
Waiting for mine after the split from Open Orphan think it’ll be March 2022 unless anyone else has anymore information?
Should be anytime now as the lockin period ended 20 Apr 22 but looking on some other boards not sure if anyone has received them via their brokers/nominees.
1 Like